- Thomas Insel, Chair of IACC
- Geraldine Dawson, Professor of Psychiatry and Behavioral Science at Duke University, and Director on Autism and Brain Development
- Alice Kao, Program staffer of the Eunice Kennedy Shriver National Institute of Child Health and Human Development - sitting in for Director Dr. Alan Guttmacher
- Isaac Kohane M.D., Harvard Pediatric Endocrinologist
- Matthew Carey, seven day public member of IACC, parent of an autistic child
- Lisa Croen PhD, epidemiologist from Kaiser Permanente
- Judy Cooper, Director of the National Institute of Deafness and Communication Disorders at NIH, sitting in for Dr. James F. Battey
- Beth Malow, M.D., Professor of Neurology and Pediatrics Department of Neurology and Pediatrics School of Medicine Vanderbilt University.
- Ashura W. Buckley, staff of the National Institute of Mental Health (NIMH), and child neurologist and sleep specialist. Clinical Investigator National Institute of Mental Health National Instituts of Health.
- Sally Burton-Hoyle, National advisory committee on autism spectrum disorder, Professor at Eastern Michigan University
- Carlos Pardo-Villamizar, M.D., John Hopkins division of neuro immunology, and infectious disorders, clinical neurologist and neuropathologist
- Judy Van De Water, Immunologist at the UC Davis MIND Institute
- Donna Kimbark, Department of Defense Autism Research Program
- Laura Kavanaugh, Health Resources and Services Administration
- Anshu Batra, Developmental Pediatrician in Los Angeles in Private Practice, 17 year old on the autistic spectrum
- Robert Naviaux, University of California San Diego, Human Geneticist, and mitochondria disorder disease specialist
- Lynn Redwood, Vice President of Collation of SafeMinds, and mom to a 20-year old autistic child
- Mustafa Sahin, Child Neurologist
- John Elder Robison, autistic adult, IACC member, and university scholar at William and Mary
- Evdokia Anagnostou, Child Neurologist at the University of Toronto
- Lawerance Scahill, from Emory University, Marcus Center Clinical Trials Program
- Daniel Coury, Developmental Behavioral Pediatrician from Nationwide Children's Hospital
- Jose Cordero, Dean of the School of Public Health, University of Puerto Rico and Member of the IACC
- Anjali Jain, Pediatrician and Health Services Researcher
- Susan Daniels, Director of The Office Of Autism Research Coordination at NIMH, Executive Secretary of the IACC
- Alison Singer, Co-Founder and President of Autism Science Foundation, mother of a 17 year old daughter with autism.
- Tiffany Farchione, M.D., Acting Director of the Psychiatry Products at FDA.
- Josie Briggs, Director of the National Center For Complementary And Alternative Medicine at NIH
- Jeff Wood, Associate Professor of Educational Psychology and Child Psychiatry at UCLA
- Rob Ring, Chief Science Officer at Autism Speaks
Detailed Biographies of Speakers
Agenda: Three Needs
- Absence of guidelines to provide clinical care for kids, and adults on the spectrum
- Continuing challenge of undetected or under recognized co-morbidities, and patient care needed
- Etiology and Pathophysiology of some sub-sets of autism with biological and co-morbid biomarkers
Anjali Jain M.D. (Timestamp 18:07)
Biological Summary; spectrum individuals have a higher frequency in all studied comorbidities such as; Disorders usually diagnosed in infancy childhood, or adolescence, factors influencing healthcare, respiratory infections, ear conditions, ill-defined conditions, immunizations and screening for infectious disease, attention deficit, conduct, and disruptive behavior disorders, eye disorders, developmental disorders, other nervous system disorders, other upper respiratory disease, unclassified E codes, viral infection, and other lower respiratory disease.
Lisa Croen Ph.D., M.P.H. (Timestamp 38:00)
Psychiatric Conditions Summary, spectrum adults have a higher frequency in all studied comorbidities such as; anxiety, depression, ADHD, Bipolar disorders, Schizophrenia, OCD, and Suicide attempts.
Isaac Kohane M.D., Ph.D. (Timestamp 50:00)
Pathology proven irritable bowel diseases (IBD) findings in children with autism, however these charted findings do not include colitis and enteritis because they did not make the criteria of IBD, but clearly is also biology negatively impacting the bowels in children with autism, and would increase the prevalence regarding biological pathology in the bowel.
- The conventional wisdom regarding the causes of autism is incomplete, divided and obscured.
- Phenotype-first strategies may massively accelerate discovery of genetic architecture.
- There is a lot of shared pathobiology across autism
- There is a lot of undiscovered heterogeneity and distinctive pathobiology within conventionally labeled diseases.
- Aggressively ecumenical approach to integrative data analysis will accelerate discovery.
Daniel Coury M.D. (Timestamp 1:11)
76.7% of autistic individuals has a comorbid behavioral condition, and 39% comorbid physical health condition, which is much higher then in any other group studied.
Discussion On Panel 1 (Timestamp 1:10)
Lawrence Scahill, Ph.D., M.S.N., M.P.H. (Timestamp 1:43)
Jeffrey Wood, Ph.D. (Timestamp 2:00)
1. Why the rate of anxiety is so prevalent in ASD? Increased daily stressors increases heightened anxiety and mood disorders (cortisol levels increase).
2. Treatment research in Cognitive Behavioral Therapy (CBT) and/or SSRIs reduce clinical anxiety, OCD, and depression in individuals with ASD
Evdokia Anagnostou M.D. (Timestamp 2:15)
- High co-occurrence of several neuropsychiatric conditions, more than expected from general population rates
- Do our diagnostic constructs map onto distinct biologic constructs
- Is there construct confusion for measurement point of view
- What does it mean of treatment development
Discussion On Panel 2 (Timestamp 2:32)
Public Comment (Timestamp 3:00)
Discussion On Public Comment (Timestamp 3:24)
Beth Malow M.D., M.S. (Timestamp 3:45)
- What do we know about sleep in autism?
- What is the evidence linking biological causes of sleep disturbance with features of ASD?
- What do we need to learn in order to treat sleep disturbance in ASD? What are the gaps? What are the opportunities?
- What autism-specific features affect proper diagnosis and treatment?
Ashura Buckley M.D. (Timestamp 4:01)
- Who are we talking about?
- What are the clinical and biological relationships between ASD and epilepsy?
- How do we address research and treatment in this population?
- Better characterization of the seizure patterns in ASD
- What is the role of ID in outcomes in ASD, in epilepsy and in ASD-epilepsy phenotypes?
- Is there a critical window for intervention that can arrest or reverse the dysfunction in neural circuitry?
- Put newly identified ASD genes in context with what is known about molecular pathways and brain circuitry
- Better animal models
- Effective collaborations across labs
- Models to identify and correct neural dysfunction in populations with both ASD/epilepsy and include people with ID
Mustafa Sahin M.D., Ph.D. (Timestamp 4:12)
Carlos Pardo-Villamizar M.D. (Timestamp 4:55)
- What is the level of evidence for immune system involvement in ASD?
- Is there evidence for a common biologic cause of the co-morbidity?
- What are the autism-specific features that affect proper diagnosis and treatment of the co-morbidity?
Judy Van de Water Ph.D.
Robert K. Naviaux M.D., Ph.D., M.S. (Timestamp 5:33)
- All ASD subjects examined to date have metabolic abnormalities
- Most of the mitochondrial dysfunction found in ASD is secondary, and is not the result of single-gene Mendelian or mtDNA defects.
- Redox, glutathione, and methylation disturbances are common (>50%)
- The Cell Danger Hypothesis
- Autism-like behaviors, metabolism, and synaptic defects were corrected by APT in mouse models of ASD
- NextGen metabolomics identifies the disturbances * mouse models and humans have the same core pathway abnormalities * previously identified as the effector pathways of the CDR